{
  "docId": "019de076-b279-75da-94b2-8ad8944b7652",
  "docSlug": "3080df08d7a75d95f523d4df26f037ae",
  "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 29 slides",
  "authorId": "matinas-biopharma",
  "authorName": "Matinas BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 29,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 32,
  "notes": "The chart shows dose-response curves where LNC formulations consistently outperform Taxol.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b279-75da-94b2-8ad8944b7652/21",
  "deckHref": "/decks/019de076-b279-75da-94b2-8ad8944b7652",
  "deckJsonHref": "/decks/019de076-b279-75da-94b2-8ad8944b7652.json",
  "deckAnchorHref": "/decks/019de076-b279-75da-94b2-8ad8944b7652#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.5,
        "x": 0.45,
        "y": 0.3
      },
      "kind": "chart",
      "text": "Dose-response chart showing % Inhibition vs LNC-Docetaxel Dose (ng/well) for MM-51, MM-53, MM-54, and Taxol.",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "91eb266a-2b63-43de-bf5f-b70461d24468",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.06,
        "y": 0.25
      },
      "kind": "list",
      "text": "RATIONALE AND NEXT STEPS: LNC Docetaxel program also provides insight into tumor uptake of LNCs; Foundation for subsequent small oligo work; In vitro results demonstrate strong LNC efficacy in inhibiting tumor cell growth; In vivo studies planned in multiple tumor models",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3aa9b6ac-d164-4614-94c1-4395fe0b838a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.37,
        "y": 0.87
      },
      "kind": "paragraph",
      "text": "MCF7 breast cancer cells",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dec16117-e8b7-42d0-bb37-1d4c88723041",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.55,
        "y": 0.2
      },
      "kind": "title",
      "text": "3 LNC Formulations Demonstrated Significantly Better Tumor Cell Inhibition Than Unformulated Drug",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "932bb09e-f372-4c84-9482-e7989a7cec76",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "In vitro Tumor Cell Inhibition with LNC Docetaxel Formulations",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2b4d80e7-b5e0-4184-93e0-bcdfb51b1f02",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}